FDMT Stock Overview
A clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
4D Molecular Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.79 |
| 52 Week High | US$36.25 |
| 52 Week Low | US$7.32 |
| Beta | 2.8 |
| 11 Month Change | -4.42% |
| 3 Month Change | -50.82% |
| 1 Year Change | -36.72% |
| 33 Year Change | -64.67% |
| 5 Year Change | n/a |
| Change since IPO | -80.77% |
Recent News & Updates
Recent updates
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
Oct 044D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 10
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11Shareholder Returns
| FDMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.8% | 2.5% | 2.2% |
| 1Y | -36.7% | 16.1% | 31.6% |
Return vs Industry: FDMT underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: FDMT underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| FDMT volatility | |
|---|---|
| FDMT Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FDMT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FDMT's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 201 | David Kirn | www.4dmoleculartherapeutics.com |
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema.
4D Molecular Therapeutics, Inc. Fundamentals Summary
| FDMT fundamental statistics | |
|---|---|
| Market cap | US$360.11m |
| Earnings (TTM) | -US$143.48m |
| Revenue (TTM) | US$17.00k |
Over9,999x
P/S Ratio-2.5x
P/E RatioIs FDMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FDMT income statement (TTM) | |
|---|---|
| Revenue | US$17.00k |
| Cost of Revenue | US$124.24m |
| Gross Profit | -US$124.22m |
| Other Expenses | US$19.26m |
| Earnings | -US$143.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.10 |
| Gross Margin | -730,723.53% |
| Net Profit Margin | -844,000.00% |
| Debt/Equity Ratio | 0% |
How did FDMT perform over the long term?
See historical performance and comparison